These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28534538)

  • 1. Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.
    Madan RA; Gulley JL
    Nat Rev Urol; 2017 Aug; 14(8):455-456. PubMed ID: 28534538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic prostate cancer vaccines: a review of the latest developments.
    Mohebtash M; Madan RA; Gulley JL; Arlen PM
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1296-301. PubMed ID: 19037836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
    Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy for Prostate Cancer.
    Venturini NJ; Drake CG
    Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 30201787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current perspectives in prostate cancer vaccines.
    Arlen PM; Gulley JL
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1052-7. PubMed ID: 19719454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Roychowdhury S; Goswami S; Ippolito JE; Priceman SJ; Pritchard CC; Sfanos KS; Subudhi SK; Simons JW; Pienta KJ; Soule HR
    Prostate; 2017 Feb; 77(2):123-144. PubMed ID: 27679977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new aspects of immunotherapy in prostate cancer.
    Ghanei M; Shohrati M; Saburi A
    Cancer Immunol Immunother; 2012 Dec; 61(12):2375-6. PubMed ID: 22736256
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in active specific immunotherapy of prostate cancer.
    Tjoa BA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.
    Janiczek M; Szylberg Ł; Kasperska A; Kowalewski A; Parol M; Antosik P; Radecka B; Marszałek A
    J Immunol Res; 2017; 2017():4861570. PubMed ID: 29109964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy: a new option for advanced prostate cancer.
    Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869
    [No Abstract]   [Full Text] [Related]  

  • 16. Promising novel immunotherapies and combinations for prostate cancer.
    Arlen PM; Mohebtash M; Madan RA; Gulley JL
    Future Oncol; 2009 Mar; 5(2):187-96. PubMed ID: 19284377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in immunotherapy for urological cancer.
    Obara W; Kato R; Kato Y; Kanehira M; Takata R
    Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
    Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
    Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.